Valuation: Shanghai RAAS Blood Products Co., Ltd.

Capitalization 41.21B 5.98B 5.15B 4.64B 4.45B 8.11B 549B 8.5B 54.84B 21.97B 264B 22.43B 21.95B 943B P/E ratio 2025 *
20.8x
P/E ratio 2026 * 17.8x
Enterprise value 41.21B 5.98B 5.15B 4.64B 4.45B 8.11B 549B 8.5B 54.84B 21.97B 264B 22.43B 21.95B 943B EV / Sales 2025 *
5.26x
EV / Sales 2026 * 4.7x
Free-Float
69.51%
Yield 2025 *
1.28%
Yield 2026 * 1.44%
1 day+1.13%
1 week-0.95%
Current month-0.79%
1 month-1.27%
3 months-5.88%
6 months-8.91%
Current year-1.58%
1 week 6.14
Extreme 6.14
6.4
1 month 6.14
Extreme 6.14
6.4
Current year 6.14
Extreme 6.14
6.57
1 year 6.14
Extreme 6.14
7.3
3 years 5.93
Extreme 5.93
8.68
5 years 4.98
Extreme 4.98
8.68
10 years 4.98
Extreme 4.98
23.88
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 39 25/10/2021
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 62 20/05/2020
Chairman 56 29/07/2024
Chairman 62 -
Change 5d. change 1-year change 3-years change Capi.($)
+1.13%-0.95%-8.24%+0.48% 5.91B
-0.66%-1.42%+10.58%-2.49% 78.5B
-2.68%+1.05%+28.29%+214.14% 56.77B
-0.18%+64.40%+64.40%+64.40% 51.31B
-0.15%+0.17%-44.65%-50.08% 49.23B
-1.71%-1.68%+28.59%-31.60% 27.6B
-2.43%+1.57%+49.16%-63.32% 21.26B
-1.43%-4.15%+37.43%+23.70% 19.37B
+6.18%-1.24%+107.47%+97.16% 17.42B
-1.21%-5.71%+21.25%+55.43% 14.22B
Average +0.31%-1.61%+29.43%+30.78% 34.16B
Weighted average by Cap. -0.35%-1.10%+24.09%+39.59%

Financials

2025 *2026 *
Net sales 7.84B 1.14B 979M 883M 848M 1.54B 105B 1.62B 10.43B 4.18B 50.16B 4.27B 4.18B 179B 8.76B 1.27B 1.09B 986M 947M 1.72B 117B 1.81B 11.66B 4.67B 56.05B 4.77B 4.67B 200B
Net income 2.02B 293M 252M 227M 218M 397M 26.9B 416M 2.69B 1.08B 12.91B 1.1B 1.07B 46.17B 2.31B 335M 288M 260M 250M 454M 30.77B 476M 3.07B 1.23B 14.77B 1.26B 1.23B 52.82B
Net Debt - -
Logo Shanghai RAAS Blood Products Co., Ltd.
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.
Employees
3,350
Date Price Change Volume
06/03/26 6.240 ¥ +1.13% 24,251,710
05/03/26 6.170 ¥ 0.00% 25,126,600
04/03/26 6.170 ¥ -2.06% 51,530,880
03/03/26 6.300 ¥ -0.79% 47,802,470
02/03/26 6.350 ¥ +0.95% 57,485,720
Trader
-
Investor
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.240
Average target price
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002252 Stock